Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Acetaminophen | The serum concentration of Acetaminophen can be increased when it is combined with Motesanib. |
| Propacetamol | The serum concentration of Propacetamol can be increased when it is combined with Motesanib. |
| Salmon calcitonin | The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Motesanib. |
| Thyrotropin alfa | The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Motesanib. |
| Follitropin | The therapeutic efficacy of Follitropin can be decreased when used in combination with Motesanib. |
| Liothyronine | The therapeutic efficacy of Liothyronine can be decreased when used in combination with Motesanib. |
| Carbimazole | The therapeutic efficacy of Carbimazole can be decreased when used in combination with Motesanib. |
| Levothyroxine | The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Motesanib. |
| Propylthiouracil | The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Motesanib. |
| Methimazole | The therapeutic efficacy of Methimazole can be decreased when used in combination with Motesanib. |
| Liotrix | The therapeutic efficacy of Liotrix can be decreased when used in combination with Motesanib. |
| 3,5-Diiodotyrosine | The therapeutic efficacy of 3,5-Diiodotyrosine can be decreased when used in combination with Motesanib. |
| Tiratricol | The therapeutic efficacy of Tiratricol can be decreased when used in combination with Motesanib. |
| Parathyroid hormone | The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Motesanib. |
| Teriparatide | The therapeutic efficacy of Teriparatide can be decreased when used in combination with Motesanib. |
| Potassium Iodide | The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Motesanib. |
| Dibromotyrosine | The therapeutic efficacy of Dibromotyrosine can be decreased when used in combination with Motesanib. |
| Thyroid, porcine | The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Motesanib. |
| Potassium perchlorate | The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Motesanib. |
| Protirelin | The therapeutic efficacy of Protirelin can be decreased when used in combination with Motesanib. |
| 3,5-diiodothyropropionic acid | The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Motesanib. |
| Methylthiouracil | The therapeutic efficacy of Methylthiouracil can be decreased when used in combination with Motesanib. |
| Elcatonin | The therapeutic efficacy of Elcatonin can be decreased when used in combination with Motesanib. |
| Benzylthiouracil | The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Motesanib. |
| Thyrotropin | The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Motesanib. |
| Voriconazole | The serum concentration of Motesanib can be increased when it is combined with Voriconazole. |
| Palopegteriparatide | The therapeutic efficacy of Palopegteriparatide can be decreased when used in combination with Motesanib. |